Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - CytRx Corporation (NasdaqNM:CYTR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Financials
Location
154 Technology Parkway, Suite 200
Norcross, GA 30092
Phone: (770) 368-9500
Fax: (770) 368-0622
Email: webmaster@cytrx.com
Employees (last reported count): 4
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 25%
·Over the last 6 months:
 · one insider buy; 2,000  shares
·Institutional: 4% (5% of float)
(13 institutions)
·Net Inst. Selling: 6,000  shares (+1.64%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
CytRx Corporation is engaged in the development and commercialization of pharmaceutical products. The Company's current research and development activities include Flocor, an intravenous agent for treatment of sickle cell disease and other acute vaso-occlusive disorders; and TranzFect, a delivery technology for DNA-based vaccines. The Company also has a research pipeline with opportunities in the areas of muscular dystrophy, cancer, spinal cord injury, vaccine delivery and gene therapy.
More from Market Guide: Expanded Business Description

Financial Summary
CYTR engages in the development of pharmaceutical products to treat acute sickle cell crisis and other vascular diseases and technologies to improve effectiveness of vaccines. For the six months ended 6/30/01, revenues fell 47% to $337 thousand. Net loss from continuing operations rose 40% to $2.4 million. Results reflect lower grant income and the effect of overall slowdown of the economy, partially offset by lower research and development costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Raymond Carnahan, Jr., 75
Chairman
--  
Jack Luchese, 52
Pres, CEO, Director
$368K
Mark Reynolds, 39
CFO, VP-Fin., Sec.
138K
William Fleck, 43
VP of HR
126K
J. Michael Grindel, Ph.D, 54
VP of Drug Devel.
208K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CYTRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Nov-2000
$0.469
Recent Price$0.89 
52-Week High
on 6-Nov-2000
$1.563
Beta-0.19 
Daily Volume (3-month avg)40.1K
Daily Volume (10-day avg)14.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-32.2%
52-Week Change
relative to S&P500
-9.1%
Share-Related Items
Market Capitalization$9.13M
Shares Outstanding10.3M
Float7.70M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 4 on 6-Feb-1996
Per-Share Data
Book Value (mrq)$0.41 
Earnings (ttm)-$0.18 
Earnings (mrq)-$0.12 
Sales (ttm)$0.30 
Cash (mrq)$0.20 
Valuation Ratios
Price/Book (mrq)2.20 
Price/EarningsN/A 
Price/Sales (ttm)2.96 
Income Statements
Sales (ttm)$3.03M
EBITDA (ttm)-$392.0K
Income available to common (ttm)-$1.82M
Profitability
Profit Margin (ttm)-60.2%
Operating Margin (ttm)-60.2%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-31.52%
Return on Equity (ttm)-38.89%
Financial Strength
Current Ratio (mrq)3.23 
Debt/Equity (mrq)0 
Total Cash (mrq)$2.06M
Short Interest
As of 8-Aug-2001
Shares Short4,000 
Percent of Float0.1%
Shares Short
(Prior Month)
4,000 
Short Ratio0.25 
Daily Volume16.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.